Skip to content

Couple User Preferences in Dual Purpose Prevention Products

Dual Purpose Prevention (DPP) Product Preferences Among Couples

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04023799
Acronym
CUPID
Enrollment
400
Registered
2019-07-18
Start date
2020-01-21
Completion date
2020-11-05
Last updated
2022-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Contraception Behavior, HIV Prevention

Brief summary

MTN-045 is a cross-sectional study that will utilize questionnaires, including Discrete-Choice Experiments (DCE) and joint decision tasks, to assess couples' preferences related to dual purpose prevention (DPP) products that could be used to prevent unintended pregnancies and HIV infection. Post-survey explanatory in-depth interviews (IDIs) will be conducted with a subset of participants to explore DPP product-related decisions..

Detailed description

MTN-045 is a cross-sectional study that will utilize questionnaires, including DCEs and joint decision tasks, and IDIs to assess heterosexual couples' preferences related to DPP products that could be used to prevent unintended pregnancies and HIV infection. One main goal of the study is to determine heterosexual couples' preferences for a DPP product to inform product delivery and future product design to maximize uptake and willingness to use among sub-Saharan African heterosexual couples. Another main goal of the study is to assess the level of influence of the male partner on a woman's preferences for a DPP product and on her decision-making process regarding product preferences and use. The MTN-045 study population will consist of approximately 400 heterosexual sub-Saharan African couples of reproductive age who have been in a relationship for ≥ 3 months and are interested in contraception and/or HIV prevention. Women who are currently using contraceptives as well as those not using contraceptives will be eligible. Couples who are living together as well as those not living together will be eligible. All participants will complete survey questionnaires, first separately from their partner, then followed by a joint couples' decision task. Up to 80 participants, i.e., one or both partners from a subset of up to 40 couples, will be selected to complete an IDI.

Interventions

None listed

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID)
CollaboratorNIH
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
CollaboratorNIH
National Institute of Mental Health (NIMH)
CollaboratorNIH
Microbicide Trials Network
Lead SponsorNETWORK

Study design

Observational model
ECOLOGIC_OR_COMMUNITY
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to 40 Years
Healthy volunteers
Yes

Inclusion criteria

Each member of the couple must meet all of the following criteria to be eligible for inclusion in the study, and both members of the couple must be willing and eligible for the couple to enroll: 1. Able and willing to provide written informed consent in one of the study languages. 2. Able and willing to complete the required study procedures. 3. Currently in a heterosexual relationship (living together or not) for at least 3 months (by self-report) with the other member of the couple. 4. At time of Enrollment, expressed interest in contraception and/or HIV prevention (by self-report). For female partner: 5. Between the ages of 18 to 40 years (inclusive) at Enrollment, verified per site standard operating procedures (SOPs). 6. HIV negative (by self-report). For male partner: 7. Aged 18 years or older at Enrollment, verified per site SOPs.

Exclusion criteria

Potential participants who meet the following criteria will be excluded from the study along with their partner: 1\. Has any significant medical condition or other condition that, in the opinion of the Investigator of Record (IoR)/designee, would preclude informed consent, make study participation unsafe (including risk for IPV as a result of study participation), complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives.

Design outcomes

Primary

MeasureTime frameDescription
Attributes of a DPP product that influence preferences among heterosexual couples12-15 months during Q2 2019/Q4 2020Survey questionnaires
Differences in DPP product attribute preferences when comparing individual to couples' choices (e.g., woman's individual preferences vs. preferences indicated through the joint couples decision task)12-15 months during Q2 2019/Q4 2020Discrete-Choice Experiments (DCE)

Secondary

MeasureTime frameDescription
Salient relationship-based and decision-making factors that influence DPP product interest and preferences12-15 months during Q2 2019/Q4 2020Survey questionnaires
Differences in attributes salient to preferences by sociodemographic factors such as age and parity that may reflect lifecourse stage12-15 months during Q2 2019/Q4 2020Survey questionnaires

Other

MeasureTime frameDescription
Differences in product preferences, when comparing individual to couples' choices, that characterize the male partner's role in females' preferences12-15 months during Q2 2019/Q4 2020Discrete-Choice Experiments (DCE)
Likelihood of using each DPP product, overall and by subgroup, as estimated through analysis of DCE data12-15 months during Q2 2019/Q4 2020Discrete-Choice Experiments (DCE)
Salient relationship characteristics, norms and communication factors that influenced participants' decision-making process12-15 months during Q2 2019/Q4 2020Survey questionnaires

Countries

Uganda, Zimbabwe

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026